These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 18571950)

  • 1. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
    Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.
    Zhang S; Bagshaw R; Hilson W; Oho Y; Hinek A; Clarke JT; Callahan JW
    Biochem J; 2000 Jun; 348 Pt 3(Pt 3):621-32. PubMed ID: 10839995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast screening for chaperone therapy in beta-galactosidosis.
    Iwasaki H; Watanabe H; Iida M; Ogawa S; Tabe M; Higaki K; Nanba E; Suzuki Y
    Brain Dev; 2006 Sep; 28(8):482-6. PubMed ID: 16617000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency.
    Higaki K; Li L; Bahrudin U; Okuzawa S; Takamuram A; Yamamoto K; Adachi K; Paraguison RC; Takai T; Ikehata H; Tominaga L; Hisatome I; Iida M; Ogawa S; Matsuda J; Ninomiya H; Sakakibara Y; Ohno K; Suzuki Y; Nanba E
    Hum Mutat; 2011 Jul; 32(7):843-52. PubMed ID: 21520340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel pseudodeficiency allele in the GLB1 gene in a carrier of GM1 gangliosidosis.
    Gort L; Santamaria R; Grinberg D; Vilageliu L; Chabás A
    Clin Genet; 2007 Aug; 72(2):109-11. PubMed ID: 17661814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
    Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis.
    Caciotti A; Donati MA; Boneh A; d'Azzo A; Federico A; Parini R; Antuzzi D; Bardelli T; Nosi D; Kimonis V; Zammarchi E; Morrone A
    Hum Mutat; 2005 Mar; 25(3):285-92. PubMed ID: 15714521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis.
    Suzuki Y; Ichinomiya S; Kurosawa M; Ohkubo M; Watanabe H; Iwasaki H; Matsuda J; Noguchi Y; Takimoto K; Itoh M; Tabe M; Iida M; Kubo T; Ogawa S; Nanba E; Higaki K; Ohno K; Brady RO
    Ann Neurol; 2007 Dec; 62(6):671-5. PubMed ID: 17994547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
    Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.
    Matsuda J; Suzuki O; Oshima A; Yamamoto Y; Noguchi A; Takimoto K; Itoh M; Matsuzaki Y; Yasuda Y; Ogawa S; Sakata Y; Nanba E; Higaki K; Ogawa Y; Tominaga L; Ohno K; Iwasaki H; Watanabe H; Brady RO; Suzuki Y
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15912-7. PubMed ID: 14676316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
    Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
    Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four novel mutations in patients from the Middle East with the infantile form of GM1-gangliosidosis.
    Georgiou T; Drousiotou A; Campos Y; Caciotti A; Sztriha L; Gururaj A; Ozand P; Zammarchi E; Morrone A; D'Azzo A
    Hum Mutat; 2004 Oct; 24(4):352. PubMed ID: 15365997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis.
    Mohamed FE; Al Sorkhy M; Ghattas MA; Al-Gazali L; Al-Dirbashi O; Al-Jasmi F; Ali BR
    Hum Genet; 2020 May; 139(5):657-673. PubMed ID: 32219518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
    Hofer D; Paul K; Fantur K; Beck M; Bürger F; Caillaud C; Fumic K; Ledvinova J; Lugowska A; Michelakakis H; Radeva B; Ramaswami U; Plecko B; Paschke E
    Hum Mutat; 2009 Aug; 30(8):1214-21. PubMed ID: 19472408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis.
    Higaki K; Ninomiya H; Suzuki Y; Nanba E
    Future Med Chem; 2013 Sep; 5(13):1551-8. PubMed ID: 24024947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of the beta-galactosidase-carboxypeptidase complex in GM1-gangliosidosis and beta-galactosialidosis fibroblasts.
    D'Agrosa RM; Hubbes M; Zhang S; Shankaran R; Callahan JW
    Biochem J; 1992 Aug; 285 ( Pt 3)(Pt 3):833-8. PubMed ID: 1497621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts.
    Hossain MA; Higaki K; Shinpo M; Nanba E; Suzuki Y; Ozono K; Sakai N
    Brain Dev; 2016 Feb; 38(2):175-80. PubMed ID: 26259553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations.
    Hofer D; Paul K; Fantur K; Beck M; Roubergue A; Vellodi A; Poorthuis BJ; Michelakakis H; Plecko B; Paschke E
    Clin Genet; 2010 Sep; 78(3):236-46. PubMed ID: 20175788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of GM1-gangliosidosis type I: glycosphingolipid profiles of urine and transformed lymphocytes and beta-D-galactosidase activities in peripheral lymphocytes, cultured skin fibroblasts and transformed lymphocytes.
    Asano K; Shindo N; Nakasuji M; Inamori K; Ohta M; Matsushita T; Yamaguchi M; Oshima M
    Jpn J Exp Med; 1990 Apr; 60(2):73-9. PubMed ID: 2117086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.